Silence Therapeutics plc
About Silence Therapeutics plc
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $559.0K
- Net income
- -$88.6M
- Total assets
- $131.4M
- Market cap
- $291.4M
- Gross margin
- 61.5%
- Operating margin
- -16292.8%
- Net margin
- -15851.9%
Source: SEC EDGAR · updated Jun 8, 2026
Financial statements
Income statement
- Revenue
- $559.0K
- Cost of revenue
- $215.0K
- Gross profit
- $344.0K
- Operating expenses
- $91.4M
- Operating income
- -$91.1M
- Income tax
- $11.0K
- Net income
- -$88.6M
- EPS (basic)
- $-0.63
- EPS (diluted)
- $-0.63
Balance sheet
- Total assets
- $131.4M
- Current assets
- $118.7M
- Total liabilities
- $69.1M
- Current liabilities
- $13.6M
- Shareholders’ equity
- $62.3M
Cash flow
- Operating cash flow
- -$62.3M
- Investing cash flow
- -$48.0M
- Financing cash flow
- $15.0K
- Net cash flow
- -$110.1M
Statements via Polygon.io (SEC filings)
- Market cap
- $291.4M
- EPS (diluted)
- $-0.63
- Shares outstanding
- 46.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 8, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $88.6M in FY2025.
- Gross margin of 61.5%, net margin -15851.9%.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Silence Therapeutics plc.
Write a review
News about Silence Therapeutics plc
News & sentiment via Polygon.io
